Posted by Michael Wonder on 03 Aug 2020
Imara announces IMR-687 granted fast track designation and rare paediatric disease designation for treatment of beta-thalassaemia
30 July 2020 - Imara today announced the U.S. FDA has granted fast track designation and rare paediatric disease designation for its lead clinical asset, IMR-687, for the treatment of beta-thalassemia.
The FDA previously granted orphan drug designation for IMR-687 for the treatment of patients with beta-thalassemia and orphan drug, fast track and rare paediatric disease designations for the treatment of patients with sickle cell disease.
